Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 October 2017

  • Email
  • Help

News

13/10/2017

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 October 2017

One generic medicine recommended for approval

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended one generic medicine for approval at its October meeting: Tacforius (tacrolimus), for prophylaxis and treatment of transplant rejection.

Six recommendations on extensions of therapeutic indications

The Committee recommended extensions of indications for Alecensa, Bydureon, Cubicin, Faslodex, Pegasys and Zytiga.

Request for re-examination of a CHMP recommendation

The applicant for Raxone (idebenone) has requested a re-examination of the Committee’s negative opinion for this medicine adopted at the September 2017 meeting. The CHMP will now re-examine this opinion and issue a final recommendation.

For more information on this negative opinion, please see the questions-and-answers document in the grid below.

Agenda and minutes

The agenda of the October 2017 meeting is published on EMA’s website. Minutes of the September 2017 CHMP meeting will be published in the coming weeks.

CHMP statistics

Key figures from the October 2017 CHMP meeting are presented in the graphic below.

More information on all other outcomes of the CHMP October 2017 meeting is available in the grid below.

CHMP_highlights_October_2017

Download image in PDF format

Positive recommendation on new generic medicine 

Name of medicineTacforius 
INNtacrolimus 
Marketing-authorisation applicantTeva B.V.
Therapeutic indicationProphylaxis and treatment of transplant rejection
More informationSummary of opinion for Tacforius

 

Positive recommendations on extensions of therapeutic indications

Name of medicineAlecensa 
INNalectinib
Marketing-authorisation holderRoche Registration Limited
More informationSummary of opinion for Alecensa

          

Name of medicineBydureon 
INNexenatide 
Marketing-authorisation holderAstraZeneca AB
More informationSummary of opinion for Bydureon

  

Name of medicineCubicin 
INNdaptomycin 
Marketing-authorisation holderMerck Sharp & Dohme Limited
More informationSummary of opinion for Cubicin

     

Name of medicineFaslodex 
INNfulvestrant
Marketing-authorisation holderAstraZeneca UK Ltd
More informationSummary of opinion for Faslodex

  

Name of medicine Pegasys
INNpeginterferon alfa-2a 
Marketing-authorisation holderRoche Registration Limited
More informationSummary of opinion for Pegasys

 

Name of medicineZytiga 
INNabiraterone acetate 
Marketing-authorisation holderJanssen-Cilag International NV
More informationSummary of opinion for Zytiga

 

Re-examination of recommendation for extension of indication

Name of medicineRaxone 
INNidebenone
Marketing-authorisation holderSanthera Pharmaceuticals (Deutschland) GmbH
More informationQuestions and answers on Raxone

  

Outcome of re-examination of arbitration procedure

Name of medicineAlcover 750 mg, 1250 mg, 1750 mg granules
INNsodium oxybate
Marketing-authorisation holderD&A Pharma
More informationQuestions and answers on Alcover 750 mg, 1250 mg, 1750 mg granules

 

Other updates

Overview of (invented) names reviewed in September 2017 by the Name Review Group (NRG)
Scientific advice and protocol assistance
Recommendations on eligibility to PRIME scheme

 

How helpful is this page?

Average rating:

 Based on 5 ratings

Add your rating:

See all ratings
2 ratings
0 ratings
0 ratings
0 ratings
3 ratings
    

Tell us more

Related content

Please note that not all documents associated with this page are published at the same time. This page is updated with new documents as soon as they become available. Therefore, users are asked to check the page regularly.

Contact point:

EMA Press office
Tel. +44 (0)20 3660 8427
E-mail: press@ema.europa.eu
Follow us on Twitter @EMA_News